Bio-Path Holdings Inc (BPTH)
2.14
-0.20
(-8.55%)
USD |
NASDAQ |
May 17, 16:00
2.15
+0.01
(+0.47%)
After-Hours: 20:00
Bio-Path Holdings SG&A Expense (Quarterly): 0.757M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.757M |
September 30, 2023 | 0.984M |
June 30, 2023 | 1.191M |
March 31, 2023 | 1.303M |
December 31, 2022 | 1.123M |
September 30, 2022 | 1.193M |
June 30, 2022 | 1.159M |
March 31, 2022 | 1.261M |
December 31, 2021 | 1.209M |
September 30, 2021 | 1.088M |
June 30, 2021 | 1.049M |
March 31, 2021 | 1.187M |
December 31, 2020 | 1.011M |
September 30, 2020 | 0.97M |
June 30, 2020 | 1.013M |
March 31, 2020 | 1.336M |
December 31, 2019 | 1.124M |
September 30, 2019 | 0.896M |
June 30, 2019 | 0.966M |
March 31, 2019 | 1.122M |
December 31, 2018 | 0.80M |
September 30, 2018 | 0.74M |
June 30, 2018 | 0.852M |
March 31, 2018 | 0.987M |
December 31, 2017 | 0.516M |
Date | Value |
---|---|
September 30, 2017 | 0.942M |
June 30, 2017 | 0.845M |
March 31, 2017 | 0.97M |
December 31, 2016 | 0.727M |
September 30, 2016 | 0.681M |
June 30, 2016 | 0.757M |
March 31, 2016 | 0.849M |
December 31, 2015 | 0.592M |
September 30, 2015 | 0.52M |
June 30, 2015 | 0.599M |
March 31, 2015 | 0.786M |
December 31, 2014 | 0.8662M |
September 30, 2014 | 0.7134M |
June 30, 2014 | 0.7545M |
March 31, 2014 | 0.3809M |
December 31, 2013 | 0.3441M |
September 30, 2013 | 0.8102M |
June 30, 2013 | 0.2405M |
March 31, 2013 | 0.2398M |
December 31, 2012 | 0.2565M |
September 30, 2012 | 0.2461M |
June 30, 2012 | 0.2522M |
March 31, 2012 | 0.2313M |
December 31, 2011 | 0.2226M |
September 30, 2011 | 0.3274M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.757M
Minimum
Dec 2023
1.336M
Maximum
Mar 2020
1.096M
Average
1.123M
Median
Dec 2022
SG&A Expense (Quarterly) Benchmarks
INVO Bioscience Inc | 1.856M |
Perspective Therapeutics Inc | 5.878M |
EyePoint Pharmaceuticals Inc | 14.11M |
Palatin Technologies Inc | 2.033M |
Lumos Pharma Inc | 4.173M |